Skip to content

Study · Randomized controlled trial · n = 19 · 2005

2 results

Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.

Diamond LE, Earle DC, Garcia WD, Spana C

Urology1 Apr 2005Cited by 33 (Europe PMC)

PMID15833522 (opens in a new tab)DOI10.1016/j.urology.2004.10.060 (opens in a new tab)PepBankPUB-15833522
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In men with erectile dysfunction, intranasal PT‑141 plus sildenafil gave a greater erectile response than sildenafil alone.

    In plain wordsIn men with erectile dysfunction, low-dose PT‑141 plus sildenafil gave a stronger erectile response than sildenafil alone.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseErectile response (RigiScan)
    Study

    n = 19

    Comparator
    Sildenafil 25 mg alone
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    7.5 mg · intranasalAs given in this study (human).

    Source sentences

    Summary
    The erectile response induced by co-administration of PT-141 and sildenafil was significantly greater than the response elicited by administration of sildenafil alone.
    1 context sentence
    Summary · context
    Nineteen patients with erectile dysfunction who were responders to either Viagra or Levitra by self-report were given 25 mg sildenafil and 7.5 mg intranasal PT-141, 25 mg sildenafil and an intranasal placebo spray, and a placebo tablet and an intranasal placebo spray in a randomized cross-over design.
  2. 02HumanRandomized controlled trialSafety outcome

    In men with erectile dysfunction, PT‑141 plus sildenafil was well tolerated, with no new adverse events and no increase in frequency or severity compared with monotherapy.

    In plain wordsIn men with erectile dysfunction, PT‑141 plus sildenafil caused no new side effects and no more or worse side effects than sildenafil alone.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changeAdverse events of co-administration
    Study

    n = 19

    Comparator
    Sildenafil 25 mg alone
    Outcome group
    Adverse events · Whole body
    Studied dose
    7.5 mg · intranasalAs given in this study (human).

    Source sentences

    Summary
    Co-administration of PT-141 and sildenafil was safe and well-tolerated and did not result in new adverse events or adverse events that were increased in frequency or severity compared with monotherapy.
    1 context sentence
    Summary · context
    Nineteen patients with erectile dysfunction who were responders to either Viagra or Levitra by self-report were given 25 mg sildenafil and 7.5 mg intranasal PT-141, 25 mg sildenafil and an intranasal placebo spray, and a placebo tablet and an intranasal placebo spray in a randomized cross-over design.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.